A novel platform for attenuating immune hyperactivity using EXO-CD24 in COVID-19 and beyond
Article
[키워드] adverse event
anti-inflammatory drug
CD24
cells
characterized
Combination
COVID-19
COVID-19 patient
cytokine
Cytokine storm
develop
displaying
doses
Efficacy
examined
EXO-CD24
Exosome
Exosomes
exosomes.
hyper-inflammatory response
hyperactivity
immune
in vitro
in vivo
Inflammatory marker
inhibit
interfere
life-threatening
lung
murine
NF-kB pathway
PAMPs
pathogen-associated molecular pattern
Patient
platform
produced
proportion
purified
randomized study
recruited
reduced
required
severity
suppress
systemic disease
therapeutic
Treatment
viral clearance
[DOI] 10.15252/emmm.202215997 PMC 바로가기 [Article Type] Article
[DOI] 10.15252/emmm.202215997 PMC 바로가기 [Article Type] Article